HSPA1A and breast carcinoma: The results confirmed the on-target activity of the two PPI inhibitors in breast cancer cell lines, and suggested that Hsp70-Bim PPI, rather than Hsp70-Bag3 PPI or Hsp70 itself, protects MCF-7/TAM-R and T47D/TAM-R.